Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1071-1079, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-888520
ABSTRACT
OBJECTIVE@#To compare the efficacy and safety of different doses of daunorubicin combined with a standard dose of cytarabine as induction chemotherapy in newly diagnosed primary acute myeloid leukemia (AML) patients.@*METHODS@#The clinical data and outcome were retrospectively analyzed in 86 newly diagnosed primary AML patients who were under 65 years old and treated with daunorubicin combined with cytarabine (DA regimen) at West China Hospital of Sichuan University from January 2017 to June 2019. Patients were divided into 2 groups based on the dose of daunorubicin they received, 35 cases in the escalated-dose group [75 mg/(m@*RESULTS@#Median follow-up time of all the patients was 15 months. The CR rate and MRD@*CONCLUSION@#The escalated dose of daunorubicin can induce higher complete remission rate, deeper remission and longer duration of remission without increasing adverse events in newly diagnosed primary AML patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Remission Induction
/
Leukemia, Myeloid, Acute
/
Antineoplastic Combined Chemotherapy Protocols
/
Daunorubicin
/
Retrospective Studies
/
Cytarabine
/
Induction Chemotherapy
Type of study:
Diagnostic study
/
Observational study
Limits:
Aged
/
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS